EML4 and adenocarcinoma: In summary, our real‐world study showed that patients harboring EML4‐ALK rearrangement tended to be younger at diagnosis, and more of them were nonsmokers and pathological diagnosed with adenocarcinoma compared with those without ALK rearrangement and EGFR mutation.